arrow
E

Erika Zecca

azienda ospedaliero-universitaria maggiore della carita
H指数:11
被引数:721

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Higher 25(OH)D Levels at Admission Predict a Favorable Disease Evolution in Moderate-to-Severe COVID-19 Patients

入院时较高水平的25(OH)D可预测中重度COVID-19患者疾病向良好方向发展

2026-04-160
OAAI
SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort

由于抗病毒免疫反应受损,炎症性自身免疫性疾病或接受霉酚酸酯治疗的肝移植患者的SARS-CoV-2感染风险更高: RIVALSA前瞻性队列的扩展随访结果

2023-07-206
OAAI
Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial
2023-03-0415
OAAI
Baseline Plasma Osteopontin Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients
2023-02-259
OAAI
CGRP Plasma Levels Correlate with the Clinical Evolution and Prognosis of Hospitalized Acute COVID-19 Patients
2022-09-2612
OAAI
Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort

正在进行的霉酚酸酯治疗削弱了慢性炎症性自身免疫性疾病或肝移植受者的Anti-SARS-CoV-2疫苗接种反应: RIVALSA前瞻性队列的结果

2022-08-1217
OAAI
Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge

出院四个月后新型冠状病毒肺炎患者的呼吸和心理物理后遗症

2021-01-27303
OAAI